For HeartSciences CEO Andrew Simpson, the pandemic's fallout only underscores the urgent need for better cardiac diagnostic tools. HeartSciences Bets Big on AI Amid Surging Heart Disease Deaths In a…
In recent news, HeartSciences has made significant strides in the fight against heart disease among diabetic patients. © Provided by New York Tech In recent news, HeartSciences has made significant strides…
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS;…
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes. Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and…
Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming…
Excerpt from the Today Show. Watch the video using the following link: heartsciences.com/wp-content/uploads/2024/02/The-cutting-edge-way-doctors-are-using-AI-to-save-lives_1.mp4
